IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v36y2018i2d10.1007_s40273-017-0579-0.html
   My bibliography  Save this article

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil

Author

Listed:
  • Livia Lovato Pires de Lemos

    (Universidade Federal de Minas Gerais
    Universidade Federal de Minas Gerais)

  • Augusto Afonso Guerra Júnior

    (Universidade Federal de Minas Gerais
    Universidade Federal de Minas Gerais)

  • Marisa Santos

    (Núcleo de Avaliação de Tecnologias em Saúde, Instituto Nacional de Cardiologia)

  • Carlos Magliano

    (Núcleo de Avaliação de Tecnologias em Saúde, Instituto Nacional de Cardiologia)

  • Isabela Diniz

    (Universidade Federal de Minas Gerais
    Universidade Federal de Minas Gerais)

  • Kathiaja Souza

    (Departamento de Gestão e Incorporação de Tecnologias em Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Ministério da Saúde
    Universidade Federal de São Paulo)

  • Ramon Gonçalves Pereira

    (Universidade Federal de Minas Gerais)

  • Juliana Alvares

    (Universidade Federal de Minas Gerais
    Universidade Federal de Minas Gerais)

  • Brian Godman

    (Karolinska University Hospital Huddinge
    University of Strathclyde
    University of Liverpool Management School)

  • Marion Bennie

    (University of Strathclyde)

  • Ivan Ricardo Zimmermann

    (Departamento de Gestão e Incorporação de Tecnologias em Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Ministério da Saúde)

  • Vânia Crisitna Canuto Santos

    (Departamento de Gestão e Incorporação de Tecnologias em Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Ministério da Saúde)

  • Clarice Alegre Pretramale

    (Departamento de Gestão e Incorporação de Tecnologias em Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Ministério da Saúde)

  • Francisco de Assis Acurcio

    (Universidade Federal de Minas Gerais
    Universidade Federal de Minas Gerais
    Universidade Federal de Minas Gerais)

Abstract

In Brazil, inclusion and exclusion of health technologies within the Unified Health System (SUS) is the responsibility of the National Committee for Health Technology Incorporation (CONITEC). A recent Cochrane systematic review demonstrated that intramuscular interferon beta 1a (IFN-β-1a-IM) was inferior to the other beta interferons (IFN-βs) for multiple sclerosis (MS). As a result, CONITEC commissioned an analysis to review possible disinvestment within SUS. The objective of this paper is to describe the disinvestment process for IFN-β-1a-IM in Brazil. The first assessment comprised a literature review and mixed treatment comparison meta-analysis. The outcome of interest was the proportion of relapse-free patients in 2 years. This analysis confirmed the inferiority of IFN-β-1a-IM. Following this, CONITEC recommended disinvestment, with the decision sent for public consultation. More than 3000 contributions were made on CONITEC’s webpage, most of them against the preliminary decision. As a result, CONITEC commissioned a study to assess the effectiveness of IFN-β-1a-IM among Brazilian patients in routine clinical care. The second assessment involved an 11-year follow-up of a non-concurrent cohort of 12,154 MS patients developed by deterministic-probabilistic linkage of SUS administrative databases. The real-world assessment further demonstrated that IFN-β-1a-IM users had a statistically higher risk of treatment failure, defined as treatment switching or relapse treatment or death, with the assessment showing that IFN-β-1a-IM was inferior to the other IFN-βs and to glatiramer acetate in both direct and indirect analysis. In the drug ranking with 40,000 simulations, IFN-β-1a-IM was the worst option, with a success rate of only 152/40,000. Following this, CONITEC decided to exclude the intramuscular presentation of IFN-β from the current MS treatment guidelines, giving patients who are currently on this treatment the option of continuing until treatment failure. In conclusion, we believe this is the first example of this new disinvestment process in action, providing an exemplar for other treatments in Brazil as well as other countries.

Suggested Citation

  • Livia Lovato Pires de Lemos & Augusto Afonso Guerra Júnior & Marisa Santos & Carlos Magliano & Isabela Diniz & Kathiaja Souza & Ramon Gonçalves Pereira & Juliana Alvares & Brian Godman & Marion Bennie, 2018. "The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil," PharmacoEconomics, Springer, vol. 36(2), pages 161-173, February.
    • Handle: RePEc:spr:pharme:v:36:y:2018:i:2:d:10.1007_s40273-017-0579-0
    DOI: 10.1007/s40273-017-0579-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0579-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-017-0579-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Bonny Parkinson & Catherine Sermet & Fiona Clement & Steffan Crausaz & Brian Godman & Sarah Garner & Moni Choudhury & Sallie-Anne Pearson & Rosalie Viney & Ruth Lopert & Adam Elshaug, 2015. "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review," PharmacoEconomics, Springer, vol. 33(9), pages 905-924, September.
    2. Ulrik Hesse & Brian Godman & Max Petzold & Andrew Martin & Rickard Malmström, 2013. "Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 677-685, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Isabela Maia Diniz & Augusto Afonso Guerra Junior & Livia Lovato Pires de Lemos & Kathiaja M Souza & Brian Godman & Marion Bennie & Björn Wettermark & Francisco de Assis Acurcio & Juliana Alvares & El, 2018. "The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil," PLOS ONE, Public Library of Science, vol. 13(6), pages 1-14, June.
    2. Viviane Cássia Pereira & Jorge Otávio Maia Barreto & Francisco Assis da Rocha Neves, 2019. "Health technology reassessment in the Brazilian public health system: Analysis of the current status," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-18, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    2. Angelo Claudio Palozzo & Andrea Messori, 2016. "Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”," PharmacoEconomics, Springer, vol. 34(4), pages 419-420, April.
    3. Lei Chen & Ying Yang & Mi Luo & Borui Hu & Shicheng Yin & Zongfu Mao, 2020. "The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China," IJERPH, MDPI, vol. 17(24), pages 1-11, December.
    4. Peter Ghijben & Dennis Petrie & Silva Zavarsek & Gang Chen & Emily Lancsar, 2021. "Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients," PharmacoEconomics, Springer, vol. 39(7), pages 741-756, July.
    5. Hye-Young Kwon & Brian Godman, 2017. "Drug Pricing in South Korea," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 447-453, August.
    6. Sabine Vogler & Peter Schneider & Nina Zimmermann, 2019. "Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing," PharmacoEconomics - Open, Springer, vol. 3(3), pages 303-309, September.
    7. Karin Dam Petersen & Gang Chen & Christine Mpundu-Kaambwa & Katherine Stevens & John Brazier & Julie Ratcliffe, 2018. "Measuring Health-Related Quality of Life in Adolescent Populations: An Empirical Comparison of the CHU9D and the PedsQLTM 4.0 Short Form 15," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 29-37, February.
    8. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
    9. Livio Garattini & Alessandro Curto, 2016. "Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?," PharmacoEconomics, Springer, vol. 34(10), pages 967-969, October.
    10. Hofmann, Bjørn, 2020. "Biases distorting priority setting," Health Policy, Elsevier, vol. 124(1), pages 52-60.
    11. Rotteveel, A.H. & Reckers-Droog, V.T. & Lambooij, M.S. & de Wit, G.A. & van Exel, N.J.A., 2021. "Societal views in the Netherlands on active disinvestment of publicly funded healthcare interventions," Social Science & Medicine, Elsevier, vol. 272(C).
    12. Craig Mitton & Brayan V. Seixas & Stuart Peacock & Michael Burgess & Stirling Bryan, 2019. "Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 573-576, October.
    13. Viviane Cássia Pereira & Jorge Otávio Maia Barreto & Francisco Assis da Rocha Neves, 2019. "Health technology reassessment in the Brazilian public health system: Analysis of the current status," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-18, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:36:y:2018:i:2:d:10.1007_s40273-017-0579-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.